· Education · Research Desk
A Biomedicine & Pharmacotherapy review frames peptide-drug conjugates (PDCs) as the emerging successor to antibody-drug conjugates in precision oncology.
This brief is part of the Novusyn Research news desk. We track peptide clinical readouts, regulatory actions, and pharma developments in neutral, evidence-led language for scientifically literate readers.
For related context, see the full news desk, clinical trials tracker, regulation tracker, compound directory, and guides library.